Contact Us

TOURISM NEWS

YolTech Therapeutics Announces Positive Clinical Data for YOLT-203, an In Vivo Gene Editing Therapy for Primary Hyperoxaluria Type 1 (PH1)

Feb 26, 2025

SHANGHAI,Feb. 25,2025-- YolTech Therapeutics,a clinical-stage in vivo gene editing company committed to pioneering the next generation of precision genetic medicines,today reported positive results fr

Lessons from Japan's AMR Response for the Global Community

Feb 26, 2025

https://iris.who.int/handle/10665/380481 TOKYO,Feb. 25,2025-- World Health Organization (WHO) Regional Office for the Western Pacific (WPRO) has released Japan\'s AMR Response 2013–2025 alongside Tok

BioCity Announces its selective Endothelin Type-A Receptor Antagonist, SC0062, Met the Primary Endpoint in Diabetic Kidney Disease (DKD) in a Phase 2 trial (2-SUCCEED)

Feb 26, 2025

SHANGHAI,Feb. 23,2025-- BioCityBiopharma (BioCity) announced that its selective endothelin receptor type A (ETA) antagonist,SC0062,met the 12-week primary endpoint of a reduction in proteinuria in the

XCMG and FinDreams Battery Co-Host the 3rd Super Battery Day: Pioneering Green Construction with Innovation and Collaboration

Feb 26, 2025

XUZHOU,China,Feb. 25,2025--The 3rd XCMG & FinDreams Super Battery Day was successfully held at the XCMG International Conference Center,Xuzhou,focused on cutting-edge technologies and explored new

Yatsen Announces Fourth Quarter and Full Year 2024 Financial Results

Feb 26, 2025

Conference Call to Be Held at 7:30 A.M. U.S. Eastern Time on February 25,2025 GUANGZHOU,China,Feb. 25,2025--Yatsen Holding Limited ("Yatsen" or the "Company") (NYSE: YSG),a leading

KT&G to Hold 38th Annual General Meeting

Feb 26, 2025

- Annual General Meeting on Mar. 26th,agendas include director appointment SEOUL,South Korea,Feb. 25,2025-- KT&G Corporation ("KT&G" or the "Company") (KRX:033780) held a

1 ... 81 82 83 84 85 86 87 ... 347